Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

Extensive-Stage Small-Cell Lung Cancer Clinical Trial

— CHEST RT  

Official title:

A Phase II Study of Platinum and Etoposide Chemotherapy, Durvalumab With Thoracic Radiotherapy in the First Line Treatment of Patients With Extensive-stage Small-cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05796089
• Other study ID #: TROG 20.01 CHEST RT
• Status: Recruiting
• Phase: Phase 2
• Start date: January 1, 2022
• Est. completion date: February 28, 2028

Study information

• Verified date: September 2023
• Source: Trans Tasman Radiation Oncology Group
• Contact: Bridget Rooney
• Phone: +61 2 40143911
• Email: CHESTRT[@]trog.com.au
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multi-centre, single arm, phase 2, open label clinical trial of patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) suitable for first-line platinum-based chemotherapy. The aim of the trial is to assess safety, feasibility and describe efficacy of the addition of concurrent thoracic radiotherapy to usual treatment of chemotherapy and immunotherapy (durvalumab) in patients with ES-SCLC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: February 28, 2028
• Est. primary completion date: September 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Provided written informed consent

• Histologically or cytologically documented ES-ECLC

• Thoracic disease deemed suitable for radiation therapy following initial systemic therapy

• If brain metastases present, then they are to be;

1. asymptomatic without steroid therapy may be included or

2. have required treatment (radiotherapy and/or surgery) and are clinically stable and patient is on a stable or reducing steroid dose of no more than dexamethasone 4mg/day (or equivalent)

• Patients must be considered suitable to receive platinum-based chemotherapy regimen as first-line treatment for ES-SCLC

• ECOG performance-status score of 0 or 1 at registration

• Life expectancy = 12 weeks at registration

• Body weight > 30 kg

• No prior exposure to immune-mediated therapy including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen-4, anti-programmed cell death-1, anti-programmed cell death ligand-1, and anti-programmed cell death ligand-2 antibodies, excluding therapeutic anticancer vaccines

• Adequate organ and marrow function as defined in the Protocol

• Female patients who;

1. are willing to use adequate contraceptive measures until 90 days after the final dose of trial treatment

2. are not breast feeding

3. have a negative pregnancy test prior at registration if of child bearing potential or have evidence of non-child bearing potential by fulfilling the criteria as stated in the Protocol at screening

Exclusion Criteria:

• Treatment with any of the following:

1. Concurrent chemotherapy (not relevant to patients registered prior to cycle 2 who will have received a cycle of platinum/etoposide chemotherapy), investigational product, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable

2. An investigational product during the last 4 weeks

3. High dose radiotherapy to the chest prior to systemic therapy precluding further thoracic radiation therapy. Radiation therapy outside of the chest for palliative care (i.e., bone metastasis) is allowed but must be completed before first dose of the trial medication

4. Immunosuppressive medication within 14 days before the first dose of durvalumab. Some exceptions apply

5. Live, attenuated vaccine within 30 days prior to the first dose of durvalumab

6. Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of Durvalumab. Surgical procedures to obtain a lung cancer diagnosis or for palliation are allowed

• Medical contraindication to, known allergy or hypersensitivity to durvalumab, etoposide, carboplatin (patients with allergy/hypersensitivity to carboplatin may receive cisplatin), cisplatin, or any of their excipients

• History of allogeneic organ transplantation

• Has a para-neoplastic syndrome (PNS) of autoimmune nature, requiring systemic treatment (systemic steroids or immunosuppressive agents) or has a clinical symptomatology suggesting worsening of PNS. Patients with hyponatraemia considered due to SIADH syndrome are eligible

• Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis. Some exceptions apply

• Interstitial lung disease/pulmonary fibrosis. Patients with emphysema and associated limited areas of pulmonary fibrosis are eligible

• Uncontrolled intercurrent illness

• History of another primary malignancy. Some exceptions apply

• History of leptomeningeal carcinomatosis

• History of active primary immunodeficiency

• Patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab

Related Conditions & MeSH terms

• Extensive-Stage Small-Cell Lung Cancer
• Lung Neoplasms
• Small Cell Lung Carcinoma

Intervention

Radiation:
• Thoracic Radiotherapy
Participants will receive thoracic radiotherapy to a dose of 30 Gray (Gy) in 10 fractions (3 Gy per day) concurrently with cycle 3 or 4 of chemo-immunotherapy (Group 1). Participants who are unsuitable for concurrent radiotherapy may receive consolidation radiotherapy. Consolidation thoracic radiotherapy will be administered to a dose of 30 Gy in 10 fractions, following 4 cycles of chemo-immunotherapy (Group 2). Treatment fractions will be delivered daily, where treatment should be completed within 15 days (9-10 fractions a fortnight).

Drug:
• Etoposide with Carboplatin or Cisplatin
The chemotherapy in this study is a standard treatment for extensive-stage small-cell lung cancer (EC-SCLC). The combination of chemotherapy (etoposide + carboplatin or etoposide + cisplatin) which the participant will receive is dependent on what is standard at the treatment centre. Chemotherapy will be administered via an intravenous infusion every 3 weeks (21 days) for 4 cycles.
• Durvalumab
The immunotherapy in this study is a standard treatment for ES-SCLC. Participants will receive a dose of 1500 mg of Durvalumab via an intravenous infusion every 3 weeks (21 days) for 4 cycles, concurrently with chemotherapy. A 1500 mg maintenance dose of Durvalumab will administered every 4 weeks after completion of chemotherapy (monotherapy).

Locations

Country	Name	City	State
Australia	Princess Alexandra Hospital	Brisbane	Queensland
Australia	Royal Brisbane and Women's Hospital	Brisbane	Queensland
Australia	Austin Health	Melbourne	Victoria
Australia	Peter MacCallum Cancer Centre	Melbourne	Victoria
Australia	St. Vincent's Hospital	Melbourne	Victoria
Australia	Blacktown Hospital	Sydney	New South Wales
Australia	Liverpool Hospital	Sydney	New South Wales
Australia	Westmead Hospital	Sydney	New South Wales

Sponsors (2)

Lead Sponsor	Collaborator
Trans Tasman Radiation Oncology Group	AstraZeneca

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of chemo-immunotherapy with concurrent thoracic radiotherapy	Group 1 and Group 2 will be compared for the presence of toxicity, whereby the proportion of grade 3 or higher pneumonitis and grade 3 or higher oesophagitis will be monitored using the NCI Common Terminology Criteria for Adverse Events v5.	From date of consent to 90 days after trial treatment is discontinued
Primary	Feasibility of chemo-immunotherapy with concurrent thoracic radiotherapy	Group 1 and Group 2 will be compared for the proportion of participants which received concurrent radiotherapy vs the proportion of participants which did not receive concurrent radiotherapy.; The two groups will also be assessed by the proportion of participants in which discontinued thoracic radiotherapy.	From date of consent to 90 days after trial treatment is discontinued
Secondary	Overall Survival	Overall survival will be defined as the time from the Cycle 1 day 1 of chemotherapy until the date of death by any cause. Participants who are alive by the analysis time point will be censored at the trial close out date.	12 months
Secondary	Progression free survival	Progression free survival will be defined as the time from Cycle 1 Day 1 of chemotherapy until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participant withdraws from therapy or receives another anticancer therapy prior to progression. Participants who are alive or have not progressed by the analysis time point will be censored at the latest of the dates contributing to a particular overall visit assessment.	6 and 12 months
Secondary	Patterns of failure	Patterns of failure assessed by the proportion of patients with first site of failure in: Thoracic, Extra-thoracic or cranial sites, seen on imaging (CT/MRI) and assessed by iRECIST and/or RANO-BM criteria. The first site of treatment relapse will be collected and categorised as thoracic, extra-thoracic or cranial.	From date of registration until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 152 weeks
Secondary	Time to local failure and local control	Time to thoracic local failure and proportion of participants with thoracic local control.	6 and 12 months